BiotechTube

Biomarker Testing

Pre-clinicalUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)

Conditions

Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)

Trial Timeline

Nov 1, 2009 → Dec 1, 2019

NCT ID
NCT01022086

About Biomarker Testing

Biomarker Testing is a pre-clinical stage product being developed by Roche for Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic). The current trial status is unknown. This product is registered under clinical trial identifier NCT01022086. Target conditions include Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic).

What happened to similar drugs?

20 of 20 similar drugs in Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic) were approved

Approved (20) Terminated (2) Active (0)
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus Extended-Release Oral CapsuleAstellas PharmaApproved
✅donepezil HCl + donepezil HClEisaiApproved
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
✅Intravenous ParicalcitolAbbVieApproved
✅Candesartan Cilexetil + Hydrochlorothiazide + Candesartan CilexetilAstraZenecaApproved
✅Zepatier + Ribavirin + SofosbuvirMerckApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01022086Pre-clinicalUNKNOWN

Competing Products

20 competing products in Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)

See all competitors
ProductCompanyStageHype Score
FYB206 + KeytrudaFormycon AGPhase 1
23
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
ALPS12 + obinutuzumabChugai PharmaceuticalPhase 1
36
LazertinibYuhanPhase 2
31
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Datopotamab deruxtecanDaiichi SankyoPhase 2
42
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
39
Anastrozole + Trastuzumab DeruxtecanDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Atezolizumab + CarboplatinDaiichi SankyoPhase 1/2
39
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
36
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Fezolinetant + PlaceboAstellas PharmaPhase 2
42
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPAAstellas PharmaPre-clinical
30
Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
43
Tacrolimus Extended-Release Oral CapsuleAstellas PharmaApproved
43
Roxadustat + Epoetin AlfaAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
32